Aldosterone Antagonism by 17-Spirolactosteroids

Aldosterone antagonism by 17-spirolactosteroids.

Aldosterone Antagonism and Arterial Stiffness

To the Editor: We wish to congratulate White et al1 for their evaluation of the effects of the comparative aldosterone blocker eplerenone versus the calcium antagonist amlodipine in old subjects with systolic hypertension. Until recently, eplerenone was presented as a standard antihypertensive agent, acting mainly on diastolic blood pressure, but with limited affinity for the progesterone and a...

Aldosterone antagonism in heart failure

Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction. Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure. The first was the Randomized Aldactone Evaluation Study,...

Aldosterone antagonism in chronic kidney disease.

A ngiotensin-converting enzyme (ACE) inhibitors are potent members of the arsenal to treat chronic kidney disease (CKD). By reducing blood pressure (BP) and disproportionately decreasing intraglomerular pressure, this class of drugs also reduces proteinuria and slows progression of CKD (1,2). Given the high prevalence of cardiovascular disease in this population, it is noteworthy that ACE inhib...

Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a systemic disease characterised by the formation of multiple renal cysts that adversely affect renal function. ADPKD shows significant progression with age when complications due to hypertension are most significant. The activation of the renin-angiotensin-aldosterone system (RAAS) occurs in progressive kidney disease leading to hypertens...